Key Insights

Highlights

Success Rate

86% trial completion

Published Results

416 trials with published results (11%)

Research Maturity

1765 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

7.6%

278 terminated out of 3658 trials

Success Rate

86.4%

-0.2% vs benchmark

Late-Stage Pipeline

9%

337 trials in Phase 3/4

Results Transparency

24%

416 of 1765 completed with results

Key Signals

416 with results86% success278 terminated

Data Visualizations

Phase Distribution

2,749Total
Not Applicable (1015)
Early P 1 (34)
P 1 (643)
P 2 (720)
P 3 (276)
P 4 (61)

Trial Status

Completed1,765
Unknown620
Recruiting525
Terminated278
Active Not Recruiting179
Not Yet Recruiting157

Trial Success Rate

86.4%

Benchmark: 86.6%

Based on 1765 completed trials

Clinical Trials (3658)

Showing 20 of 20 trials
NCT06593678Not ApplicableCompletedPrimary

Telerehabilitation in Cancer Patients: Optimization of Prehabilitation and Rehabilitation Following Colorectal Resection

NCT06807073Not ApplicableRecruitingPrimary

Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps

NCT07659795Phase 2RecruitingPrimary

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

NCT06242470Phase 1Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT04117100Recruiting

Advanced Endo-therapeutic Procedure : Registry-based Observational Study

NCT06806046Phase 1Active Not Recruiting

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

NCT07071714Phase 2Active Not RecruitingPrimary

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

NCT05592626Phase 1Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT07328516Enrolling By Invitation

Natural History Study of Early Life Exposures in Agriculture (ELEA)

NCT03965234Phase 1Recruiting

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

NCT04585750Phase 1Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT05694559Not ApplicableRecruiting

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics

NCT07722494Phase 3RecruitingPrimary

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

NCT07752875Phase 1Not Yet Recruiting

A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

NCT00265850Phase 3CompletedPrimary

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00001823Recruiting

Evaluation for NCI Surgery Branch Clinical Research Protocols

NCT06880055RecruitingPrimary

Shield Post-Approval Study Protocol

NCT07743723Phase 1Not Yet Recruiting

A Study of IOV-5001 in Adults With Advanced Solid Tumors

NCT07744139Not Yet RecruitingPrimary

Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis

NCT07750158Phase 3Not Yet RecruitingPrimary

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

Scroll to load more

Research Network

Activity Timeline